Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
How would you manage a patient with rheumatoid vasculitis of skin of lower extremities in the setting of osteomyelitis due to sacral pressure ulcer?
Related Questions
Do you offer LDRT for psoriatic arthritis, rheumatoid arthritis, or polymyalgia rheumatica or fibromyalgia?
Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?
How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?
What are best practices in management of severe acute infusion reaction from infliximab?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
What is your approach to the evaluation of a patient with persistent costochondritis?
How you do approach management of a patient with previously well-controlled RA, who is now having recurrent flares of multiple joints which is resistant to even high dose steroids?
Would you consider adding dupilumab to adalimumab (or other monoclonal antibodies) in a patient who has RA and refractory atopic dermatitis and already is on MTX 25 mg weekly?
How do you approach the timing of DMARD initiation in patients with active RA who are on treatment for latent TB?
For patients with RA and secondary loss of response to initial TNFi do you typically recommend an alternative TNFi or switch to a different mechanism of action?